How to Buy Pasithea Therapeutics Stock
Pasithea Therapeutics Corp
Pasithea Therapeutics Corp. , a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders.
Pasithea Therapeutics stock last closed at $0.38, up 4.11% from the previous day, and has decreased 54% in one year. It has underperformed other stocks in the Biotechnology industry by 0.56 percentage points. Pasithea Therapeutics stock is currently +22.58% from its 52-week low of $0.31, and -75.32% from its 52-week high of $1.54.
As of May 26, 2023, there are 26.13M shares of KTTA outstanding. The market value of KTTA is $9.93M. In the past 24 hours, 4644 KTTA shares were traded.
How to Buy Pasithea Therapeutics Stock
Not sure how to invest in Pasithea Therapeutics stock? Here's how.
- Figure out where to buy Pasithea Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you figure out where to buy Pasithea Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Select your method of payment and add your information.
- Evaluate Pasithea Therapeutics stock: The Pasithea Therapeutics ticker symbol is KTTA. Is Pasithea Therapeutics stock a good investment? Should you buy shares of KTTA? How do KTTA's underlying business fundamentals look? Do top analysts think Pasithea Therapeutics is a good buy? Why has KTTA's stock price moved recently? (Hint: Our stock research website can help you understand if KTTA is a good stock to buy).
- Place your KTTA trade: Decide if you will purchase KTTA shares at the current market price or use a limit order to purchase KTTA shares at a particular price.
- Keep an eye on your investment in KTTA: Create a watchlist to get the latest news on your investment in Pasithea Therapeutics stock.
Step 1: Figure out where to buy Pasithea Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy KTTA stock.
Our recommended brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Technology to Energy, New York to Hong Kong — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro now.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've picked the best brokerage, you'll need to fill out some personal details so you can buy KTTA today.
How to Open a New Account on eToro
- Click here to get started.
- Enter your personal details to create your new trading account.
- Send your details by clicking the "Create Account" button.
Step 3: Put funds into your brokerage account
Now that you've created your account on the best stock buying app, your next step is to transfer the money for your investment:
Watch the video below to see the process of depositing money into your brokerage account.
Step 4: Evaluate Pasithea Therapeutics stock
Once you have figured out the best place to buy Pasithea Therapeutics stock, it's important to research their stock prior to investing, so you truly understand the risk and upside.
Pasithea Therapeutics shares quick numbers
KTTA Zen Score
WallStreetZen was created to help average investors do better fundamental analysis quickly.
You can view all of the due diligence checks on KTTA's stock page.
Is KTTA stock undervalued?
You can use many financial metrics, analyses, models, and charts to gauge KTTA's fair value.
Using relative valuations measures:
- KTTA may be undervalued based on its P/B ratio of 0.25x, relative to Biotechnology industry P/B ratio of 5.18x
You can do more valuation research on KTTA's stock here.
KTTA Financial Health Summary
Positive Health Checks:
- KTTA has cash burn of 17315348. It has sufficient cash and short-term investments to cover this for at least one year.
- KTTA has a low debt to equity ratio of 0.07.
- There are more short-term assets than short-term liabilities on the KTTA balance sheet.
- KTTA has $29.91M in cash and short term investments. This is sufficient to cover its annual cash burn of $17.32M.
- There are more short-term assets than long-term liabilities on the KTTA balance sheet.
Negative Health Checks:
- KTTA profit margin has gone up by 178.71 percentage points in the past year, but the company is still unprofitable.
Do analysts think it's a good time to buy Pasithea Therapeutics stock
Out of 1 Wall Street analysts who give forecasts on KTTA, the consensus analyst rating on Pasithea Therapeutics is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent KTTA Analyst Recommendations
Constantine Davides, a bottom 4% analyst from EF Hutton maintains KTTA with a strong buy rating and lowers their KTTA price target from $2.30 to $2.00, on Apr 3, 2023.
You can dive deeper into what analysts are projecting on the Pasithea Therapeutics stock forecast page.
KTTA Technicals
KTTA Performance Numbers
Last year, KTTA revenue was $472.90k. Over the past one years, KTTA's revenue has increased by 3,039.7% per year. This was faster than the Biotechnology industry average of 89.01%.
Find out more about KTTA's earnings and revenue performance here.
Who is buying/selling KTTA?
In the past 12 months, executives and large shareholders at KTTA have bought more shares than they have sold.
Lawrence Steinman, Director of KTTA, was the latest KTTA insider to buy. They bought $4,900.00 worth of KTTA shares on Nov 28, 2022.
Research more about who owns KTTA shares here.
Can I get consistent income from KTTA stock?
No, Pasithea Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about KTTA
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your KTTA trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually fine for most investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a specific price, place a limit order.
Click the Open button and eToro will place the order.
If you require more help with buying stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your investment in KTTA
Now that you own some KTTA stock, you'll want to keep up with your stock purchase.
Put KTTA on a watchlist to get alerted to the latest events about your KTTA stock.
KTTA Feed
How to Buy Stock in Pasithea Therapeutics
To summarize, here are the 6 steps you need to take to buy Pasithea Therapeutics stock right now:
- Figure out where to buy Pasithea Therapeutics stock
- Sign up for a brokerage account
- Put funds into your brokerage account
- Evaluate Pasithea Therapeutics stock
- Place your KTTA trade
- Keep an eye on your investment in KTTA
If you need a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Pasithea Therapeutics, create a watchlist on WallStreetZen today.
Other Stock Buying Guides You Might Find Useful
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.